Winship Cancer Institute of Emory University (Winship) has announced leadership changes in its recently formed Cell and Molecular Biology (CMB) Research Program, effective June 1, 2020.
Wei Zhou, PhD will assume the role of leader of the CMB Research Program. Zhou, who previously served as the program's co-leader, succeeds Jing Chen, PhD in this role. Zhou's research focuses on the molecular genetics of human cancer, including the functions of tumor suppressor genes.
Cheng-Kui Qu, MD, PhD will assume the role of co-leader of the CMB Research Program. Qu is a professor in the Emory Department of Pediatrics and a researcher in the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta. His research focus includes cell signaling and metabolic regulation of leukemic cell development with a focus on leukemic stem cells.
The CMB Research Program is one of Winship's four research programs, each comprised of investigators with common scientific interests and goals. The themes of the CMB Research Program, as refined during Winship's 2019 strategic program realignment, are: (1) cancer cell metabolism, (2) cancer cell stress and survival, (3) mechanisms of invasion and metastasis, and (4) gene regulation.
"The work of the Cell and Molecular Biology Research Program is critical to identifying new markers and targets to improve cancer prevention, diagnosis, and treatment," says Walter J. Curran, Jr., MD, Winship executive director. "Winship is grateful to Wei, CK, and Jing for their exceptional leadership of a program that continues to drive foundational advances in cancer research."